Advertisement

Featured in NEJM Journal Watch: Breaking News from ACC 2014 — Physician’s First Watch

Medical News |
March 31, 2014

Featured in NEJM Journal Watch: Breaking News from ACC 2014

By the NEJM Journal Watch Editors

NEJM Journal Watch is covering the latest trials from the American College of Cardiology conference in Washington, D.C. Here are this weekend's highlights:

  • SYMPLICITY HTN-3: Catheter-based renal denervation did not lower blood pressure significantly in a sham-controlled trial.

  • U.S. CoreValve High-Risk Study: A new self-expanding bioprosthesis for transcatheter aortic-valve replacement beats surgery in patients with severe aortic stenosis.

  • CHOICE: Procedural outcomes at 30 days after transcatheter aortic valve replacement favored a balloon-expandable device (Sapien) over a self-expandable one (CoreValve), but longer and larger trials are needed to assess clinical outcomes.

  • MADIT-CRT: In an extended follow-up of patients with mild heart failure, cardiac resynchronization therapy reduced mortality in patients with left bundle-branch block, but not in those without it.

  • STABILITY: In this prospective randomized trial among patients with stable CHD, lipoprotein-associated phospholipase A2 inhibition did not improve the primary clinical outcomes.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement